TPM3 deletions cause a hypercontractile congenital muscle stiffness phenotype
- 29 September 2015
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 78 (6) , 982-994
Abstract
Objective: Mutations in TPM3, encoding Tpm3.12, cause a clinically and histopathologically diverse group of myopathies characterized by muscle weakness. We report two patients with novel de novo Tpm3.12 single glutamic acid deletions at positions ΔE218 and ΔE224, resulting in a significant hypercontractile phenotype with congenital muscle stiffness, rather than weakness, and respiratory failure in one patient.Methods: The effect of the Tpm3.12 deletions on the contractile properties in dissected patient myofibers was measured. We used quantitative in vitro motility assay to measure Ca2+ sensitivity of thin filaments reconstituted with recombinant Tpm3.12 ΔE218 and ΔE224.Results: Contractility studies on permeabilized myofibers demonstrated reduced maximal active tension from both patients with increased Ca2+ sensitivity and altered cross‐bridge cycling kinetics in ΔE224 fibers. In vitro motility studies showed a two‐fold increase in Ca2+ sensitivity of the fraction of filaments motile and the filament sliding velocity concentrations for both mutations.Interpretation: These data indicate that Tpm3.12 deletions ΔE218 and ΔE224 result in increased Ca2+ sensitivity of the troponin–tropomyosin complex, resulting in abnormally active interaction of the actin and myosin complex. Both mutations are located in the charged motifs of the actin‐binding residues of tropomyosin 3, thus disrupting the electrostatic interactions that facilitate accurate tropomyosin binding with actin necessary to prevent the on‐state. The mutations destabilize the off‐state and result in excessively sensitized excitation–contraction coupling of the contractile apparatus. This work expands the phenotypic spectrum of TPM3‐related disease and provides insights into the pathophysiological mechanisms of the actin–tropomyosin complex. Ann Neurol 2015;78:982–994Keywords
Funding Information
- Australian National Health and Medical Research Council (APP1002147, APP1022707)
- Australian Research Council (FT100100734)
- British Heart Foundation (RG/11/20/29266, FS/12/24/29568)
This publication has 43 references indexed in Scilit:
- Myofibrillar Ca2+ sensitivity is uncoupled from troponin I phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal troponin TCardiovascular Research, 2012
- Nemaline myopathy with stiffness and hypertonia associated with an ACTA1 mutationNeurology, 2012
- Changes in cross-bridge cycling underlie muscle weakness in patients with tropomyosin 3-based myopathyHuman Molecular Genetics, 2011
- Tropomyosin Position on F-Actin Revealed by EM Reconstruction and Computational ChemistryBiophysical Journal, 2011
- Infantile muscular dystrophy in Canadian aboriginals is an αB‐crystallinopathyAnnals of Neurology, 2010
- Altered myofilament function depresses force generation in patients with nebulin-based nemaline myopathy (NEM2)Journal of Structural Biology, 2010
- Thin filament length dysregulation contributes to muscle weakness in nemaline myopathy patients with nebulin deficiencyHuman Molecular Genetics, 2009
- Effect of Inorganic Phosphate on the Force and Number of Myosin Cross-Bridges During the Isometric Contraction of Permeabilized Muscle Fibers from Rabbit PsoasBiophysical Journal, 2008
- Structural basis for tropomyosin overlap in thin (actin) filaments and the generation of a molecular swivel by troponin-TProceedings of the National Academy of Sciences, 2008
- Calcium sensitizer agents: A new class of inotropic agents in the treatment of decompensated heart failureInternational Journal of Cardiology, 2005